A lawsuit was filed on behalf of investors in Bristol-Myers Squibb Co (NYSE:BMY) shares over alleged securities laws violations.
San Diego, CA -- (SBWIRE) -- 02/26/2018 -- An investor, who purchased shares of Bristol-Myers Squibb Co (NYSE:BMY), filed a lawsuit over alleged violations of Federal Securities Laws by Bristol-Myers Squibb Co in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
On August 5, 2016, Bristol-Myers Squibb Co announced that its CheckMate-026 trial investigating the use of Opdivo (nivolumab) as monotherapy had failed because it did not meet its primary endpoint of progression-free survival.
On October 9, 2016, Bristol-Myers Squibb Co disclosed the final primary analysis of CheckMate-026, including the finding that overall survival was only 14.4 months for Opdivo versus 13.2 months for chemotherapy.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) declined from $76.00 per share in July 2016 to as low as $49.03 per share on October 25, 2016.
According to the complaint the plaintiff alleges on behalf of purchasers of Bristol-Myers Squibb Co (NYSE:BMY) common shares between January 27, 2015 and October 9, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between January 27, 2015 and October 9, 2016, the Defendants failed to disclose that Bristol-Myers' CheckMate-026 trial was more likely to fail than Defendants were representing, that Bristol- Myers' CheckMate-026 trial failed more severely than the Company indicated it did in the Company's August 5, 2016 announcements and disclosures, and that, as a result of the foregoing, Defendants' statements about Bristol-Myers' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.
On February 5, 2018, Bristol-Myers Squibb Co (NYSE:BMY) reported its fourth quarter and full year financial results. Bristol-Myers Squibb Co reported that its annual Total Revenue rose from over $19.42 billion in 2016 to over $20.77 billion in 2017 and that its Net Income declined from over $4.45 billion in 2016 to over $1 billion in 2017.
Those who purchased shares of Bristol-Myers Squibb Co (NYSE:BMY) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels